EMEA-002736-PIP02-23 - paediatric investigation plan

garetosmab

Key facts

• Active Substance:
  garetosmab
• Therapeutic area:
  Congenital, familial and genetic disorders
• Decision number:
  P/0103/2024
• PIP number:
  EMEA-002736-PIP02-23
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of fibrodysplasia ossificans progressiva
• Route(s) of administration:
  Intravenous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  12/04/2024

Decision

P/0103/2024: EMA decision of 12 April 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for garetosmab (EMEA-002736-PIP02-23)

AdoptedReference Number: EMA/98369/2024